Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Ribaudo

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2015
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 StudyBabafemi O Taiwo, Ellen S Chan, Carl J Fichtenbaum, et al.
AIDS (London, England)|September 30, 2014
2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaqueMarkella V Zanni, Kathleen V Fitch, Meghan Feldpausch, et al.
The Journal of Infectious Diseases|June 29, 2012
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256Timothy J Wilkin, Christina M Lalama, John McKinnon, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|December 2, 2010
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participantsBenjamin J Grady, Eric S Torstenson, Paul J McLaren, et al.
Open Forum Infectious Diseases|March 4, 2015
Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group StudyTimothy J Henrich, Paul J McLaren, Suhas S P Rao, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 13, 2025
The Effect of Low Dose Methotrexate on Arterial Inflammation in Persons Living with Human Immunodeficiency Virus. A double-blind randomized placebo-controlled pilot trialAhmed Tawakol, Heather Ribaudo, Ashley McKhann, et al.
HIV Clinical Trials|January 18, 2011
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimenScott M Hammer, Heather Ribaudo, Roland Bassett, et al.
AIDS (London, England)|November 7, 2015
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recoveryAnthony R Cillo, Benedict B Hilldorfer, Christina M Lalama, et al.
The Journal of Antimicrobial Chemotherapy|March 11, 2021
Impact of pre-existing drug resistance on risk of virological failure in South AfricaJonathan Z Li, Natalia Stella, Manish C Choudhary, et al.
The Journal of Infectious Diseases|July 10, 2020
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency VirusEdgar T Overton, Amy Kantor, Kathleen V Fitch, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2015
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 StudyBabafemi O Taiwo, Ellen S Chan, Carl J Fichtenbaum, et al.
AIDS (London, England)|September 30, 2014
2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaqueMarkella V Zanni, Kathleen V Fitch, Meghan Feldpausch, et al.
The Journal of Infectious Diseases|June 29, 2012
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256Timothy J Wilkin, Christina M Lalama, John McKinnon, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|December 2, 2010
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participantsBenjamin J Grady, Eric S Torstenson, Paul J McLaren, et al.
Open Forum Infectious Diseases|March 4, 2015
Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group StudyTimothy J Henrich, Paul J McLaren, Suhas S P Rao, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|December 13, 2025
The Effect of Low Dose Methotrexate on Arterial Inflammation in Persons Living with Human Immunodeficiency Virus. A double-blind randomized placebo-controlled pilot trialAhmed Tawakol, Heather Ribaudo, Ashley McKhann, et al.
HIV Clinical Trials|January 18, 2011
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimenScott M Hammer, Heather Ribaudo, Roland Bassett, et al.
AIDS (London, England)|November 7, 2015
Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recoveryAnthony R Cillo, Benedict B Hilldorfer, Christina M Lalama, et al.
The Journal of Antimicrobial Chemotherapy|March 11, 2021
Impact of pre-existing drug resistance on risk of virological failure in South AfricaJonathan Z Li, Natalia Stella, Manish C Choudhary, et al.
The Journal of Infectious Diseases|July 10, 2020
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency VirusEdgar T Overton, Amy Kantor, Kathleen V Fitch, et al.
Pageof 5